Pfizer will sell its remaining stake in British consumer healthcare group Haleon , the companies said on Tuesday.

(Reuters) -Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional ...

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...

Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating ...

In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new ...

Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a research ...

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.